{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"136.5","value":"-41.3"},{"groupId":"OG001","spread":"153.1","value":"203.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Change in absolute CD4 count from baseline to post-treatment (visit 6)","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\ncyclophosphamide: Given IV\n\ndoxorubicin hydrochloride: Given IV\n\nvincristine sulfate: Given IV\n\nprednisone: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (CHOP)"},{"description":"Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nlomustine: Given PO\n\netoposide: Given PO\n\ncyclophosphamide: Given PO\n\nprocarbazine hydrochloride: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Oral Chemotherapy)"}],"paramType":"MEAN","populationDescription":"Participants who had absolute CD4 count measurements at baseline and visit 6","reportingStatus":"POSTED","timeFrame":"From baseline to 18 weeks","title":"Change in Absolute CD4 Count From Baseline to Post-treatment","type":"PRIMARY","unitOfMeasure":"cells per mm^3"}